Clovis Oncology, Inc. (CLVS)
-NasdaqGS 64.55 
1.50(2.28%) 4:00PM EDT
| Prev Close: | 66.06 |
|---|
| Open: | 66.97 |
|---|
| Bid: | N/A |
|---|
| Ask: | 73.00 x 100 |
|---|
| 1y Target Est: | 87.67 |
|---|
| Beta: | 4.366 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 62.40 - 67.04 |
|---|
| 52wk Range: | 11.19 - 86.29 |
|---|
| Volume: | 509,712 |
|---|
| Avg Vol (3m): | 313,992 |
|---|
| Market Cap: | 1.70B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -2.73 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- 3 Healthcare Stocks to Keep an Eye Onat Motley Fool(Tue, Jun 18)
- Biodel Primed To Capitalize On Next Generation Treatments In The $10B Diabetes Marketat Seeking Alpha(Tue, Jun 18)
- Jim Cramer: Buy Applied Materials, Covidien, and W.R. Grace, But Sell This Stockat Wall St. Cheat Sheet(Mon, Jun 17)
- CLOVIS ONCOLOGY, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial StatemeEDGAR Online(Mon, Jun 17)
- [video] You Ask, Cramer Answersat CNBC(Fri, Jun 14)
- CLOVIS ONCOLOGY, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a VoteEDGAR Online(Fri, Jun 14)
- Clovis Oncology Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common StockBusiness Wire(Thu, Jun 13)
- Clovis Oncology Welcomes Two New Directors to its BoardBusiness Wire(Thu, Jun 13)
- The Best Kind of Biotech Dilutionat Motley Fool(Wed, Jun 12)
- Clovis / CO-1686: Value, Derived From Data, Supports The Valuationat Seeking Alpha(Wed, Jun 12)
- Clovis 3.33M share Secondary priced at $72.00at theflyonthewall.com(Tue, Jun 11)
- Clovis Oncology Announces Upsizing and Pricing of Public Offering of Common StockBusiness Wire(Tue, Jun 11)
- Five Best-Performing Biotech Stocks of 2013 (Some May Surprise You)at TheStreet(Tue, Jun 11)
- 4 Healthcare Stock Stories Deserving of Monday Attentionat Wall St. Cheat Sheet(Mon, Jun 10)
- ASCO Stocks That Should Sizzle in the Futureat Motley Fool(Mon, Jun 10)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -2.57 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.65 |
|---|
| Mean Recommendation*: | 1.7 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally.
View More